CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a LYSA Study Based on the DESCAR-T registry

Crochet, Gilles; Couturier, Audrey; Bachy, Emmanuel; Cartron, Guillaume; Fradon, Tom; Gounot, Romain; Castilla-Llorente, Cristina; Sarkozy, Clémentine; Camus, Vincent; Chauchet, Adrien; Deconinck, Eric; Guidez, Stéphanie; Bouabdallah, Krimo; Morschhauser, Franck; Houot, Roch

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a LYSA Study Based on the DESCAR-T registry

Crochet, Gilles

;

Couturier, Audrey

;

Bachy, Emmanuel

;

Cartron, Guillaume

;

Houot, Roch

;et.al.

(2022) 64th ASH annual meeting 2022 — Location: New Orleans (10.December.2022)

Files

No attached file found for this publication.

Details

Authors

Crochet, GillesUCLouvain
Author
Couturier, Audrey
Author
Bachy, Emmanuel
Author
Cartron, Guillaume
Author
Houot, Roch
Author

Affiliations

UCLouvain(MGD) Service d'hématologie

Citations

APA
Chicago
FWB

Crochet, G., Couturier, A., Bachy, E., Cartron, G., Fradon, T., Gounot, R., Castilla-Llorente, C., Sarkozy, C., Camus, V., Chauchet, A., Deconinck, E., Guidez, S., Bouabdallah, K., Morschhauser, F., & Houot, R. (2022). CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a LYSA Study Based on the DESCAR-T registry. 64th ASH annual meeting 2022, New Orleans. https://hdl.handle.net/2078.5/272008